The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency

International Journal of COPD

Volumn 7, Issue , 2012, Pages 687-696

  Schmid, S T ^a   Koepke, J ^a   Dresel, M ^a   Hattesohl, A ^a   Frenzel, E ^b   Perez, J ^c   Lomas, D A ^d   Miranda, E ^e   Greulich, T ^a   Noeske, S ^a   Wencker, M ^f   Teschler, H ^f   Vogelmeier, C ^a   Janciauskiene, S ^b   Koczulla, A R ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF MÁLAGA   (Spain)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Augmentation therapy; Cytokines; Exhaled breath condensate; IL 8; Neutrophils; Prolastin

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; SERPINA1 PROTEIN, HUMAN;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BLOOD ANALYSIS; BREATH ANALYSIS; BRONCHUS MUCOSA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG EXPOSURE; EPITHELIUM CELL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG EMPHYSEMA; LUNG PARENCHYMA; MALE; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PROTECTION; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; SERUM GROUP PI SYSTEM; TREATMENT DURATION; AGED; BLOOD; CELL CULTURE; DRUG ADMINISTRATION; DRUG EFFECT; ENZYME REPLACEMENT; ENZYMOLOGY; GENETICS; GENOTYPE; GERMANY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEUTROPHIL; PHENOTYPE; RESPIRATORY TRACT MUCOSA; TIME; TREATMENT OUTCOME;

ADULT; AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; BIOLOGICAL MARKERS; BREATH TESTS; C-REACTIVE PROTEIN; CELLS, CULTURED; CHEMOKINES; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; FEMALE; GENOTYPE; GERMANY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUTROPHILS; PHENOTYPE; PULMONARY EMPHYSEMA; RESPIRATORY MUCOSA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872257169     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S34560     Document Type: Article

References (38)

1. Seersholm N, Kok-Jensen A. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency. Thorax. 1998;53(4):265-268.
2. Janciauskiene S, Eriksson S, Callea F, et al. Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin. Hepatology. 2004;40(5):1203-1210.
3. Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T. The discovery of? 1-antitrypsin and its role in health and disease. Respir Med. 2011;105(8):1129-1139.
4. Mahadeva R, Atkinson C, Li Z, et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol. 2005;166(2):377-386.
5. Parmar JS, Mahadeva R, Reed BJ, et al. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogen-esis of emphysema. Am J Respir Cell Mol Biol. 2002;26(6):723-730.
6. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA. 1988;260(9):1259-1264.
7. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900.
8. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360(26):2749-2757.
9. Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10(10):2260-2263.
10. Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001; 119(3):737-744.
11. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000;118(5):1480-1485.
12. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1468-1472.
13. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1345-1353.
14. Kueppers F. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Curr Med Res Opin. 2011;27(3):579-588.
15. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD phar-macological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416e69.
16. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26(3):523-548.
17. Koczulla AR, Noeske S, Herr C, et al. Ambient temperature impacts on pH of exhaled breath condensate. Respirology. 2010;15(1): 155-159.
18. Sack U, Scheibe R, Wotzel M, et al. Multiplex analysis of cytokines in exhaled breath condensate. Cytometry A. 2006;69(3):169-172.
19. Miranda E, Perez J, Ekeowa UI, et al. A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency. Hepatology. 2010;52(3):1078-1088.
20. Bals R, Beisswenger C, Blouquit S, Chinet T. Isolation and air-liquid interface culture of human large airway and bronchiolar epithelial cells. J Cyst Fibros. 2004;3(Suppl 2):49-51.
21. Janciauskiene S, Zelvyte I, Jansson L, Stevens T. Divergent effects of alpha1-antitrypsin on neutrophil activation, in vitro. Biochem Biophys Res Commun. 2004;315(2):288-296.
22. Surhone LM, Timpledon MT, Marseken SF, editors. Normality Test: Data Set, Normal Distribution, Random Variable, Model Selection, Interpretations of Probability. Betascript Publishing. 2010.
23. Dickens JA, Lomas DA. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther. 2011;5:391-405.
24. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165(11):1494-1498.
25. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106(11):1311-1319.
26. Nita I, Hollander C, Westin U, Janciauskiene SM. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res. 2005;6:12.
27. Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest. 1981;68(5):1158-1165.
28. Lomas DA, Elliott PR, Carrell RW. Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component. Eur Respir J. 1997;10(3):672-675.
29. Boring L, Gosling J, Chensue SW, et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest. 1997;100(10):2552-2561.
30. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992;307(1):97-101.
31. Capoccia BJ, Gregory AD, Link DC. Recruitment of the inflammatory subset of monocytes to sites of ischemia induces angiogenesis in a monocyte chemoattractant protein-1-dependent fashion. J Leukoc Biol. 2008;84(3):760-768.
32. Morimoto H, Hirose M, Takahashi M, et al. MCP-1 induces cardiopro-tection against ischaemia/reperfusion injury: role of reactive oxygen species. Cardiovasc Res. 2008;78(3):554-562.
33. Rouhani F, Paone G, Smith NK, Krein P, Barnes P, Brantly ML. Lung neutrophil burden correlates with increased pro-inflammatory cytokines and decreased lung function in individuals with alpha(1)-antitrypsin deficiency. Chest. 2000;117(5 Suppl 1):250S-251S.
34. Boutten A, Dehoux MS, Seta N, et al. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 1996;153(1):336-342.
35. Janciauskiene S, Larsson S, Larsson P, Virtala R, Jansson L, Stevens T. Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun. 2004; 321(3):592-600.
36. Pott GB, Chan ED, Dinarello CA, Shapiro L. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol. 2009;85(5):886-895.
37. Bergin DA, Reeves EP, Meleady P, et al.?-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest. 2010;120(12):4236-4250.
38. Sapey E, Stockley JA, Greenwood H, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(9):1176-1186.